ArticlePLoS pathogens2019
Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells.
Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- IL-17B protects against uropathogenicMicrobiology spectrum · 2026Article
- Immune Modulation by Plasmodium yoelii: Insights From Lethal and Non-Lethal Strains.Parasite immunology · 2026Review
- Immunity beyond borders: non-lethalFrontiers in immunology · 2026Article
- Overview of the host immune response toJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- Recent advances in antibody optimization based on deep learning methods.Journal of Zhejiang University. Science. B · 2025Review
- CD4Nature communications · 2024Article
- Role of TAM Receptors in Antimalarial Humoral Immune Response.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Elicitation of T-cell-derived IFN-γ-dependent immunity by highly conserved Plasmodium ovale curtisi Duffy binding protein domain region II (PocDBP-RII).Parasites & vectors · 2023Article
- Review
- Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice.Malaria journal · 2022Article
- Host-parasite interactions duringFrontiers in immunology · 2022Review
- Hemozoin-mediated inflammasome activation limits long-lived anti-malarial immunity.Cell reports · 2021Article
- Challenges in forming inferences from limited data: a case study of malaria parasite maturation.Journal of the Royal Society, Interface · 2021Article
- Lessons Learned for Pathogenesis, Immunology, and Disease of Erythrocytic Parasites:Frontiers in cellular and infection microbiology · 2021Review
- Article
- Transcriptome dynamics of CD4Nature immunology · 2020Article
- Complement in malaria immunity and vaccines.Immunological reviews · 2020Review
- Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.Frontiers in immunology · 2020Article
- Stopping Plasmodium Parasite Invasion by Boosting Humoral Immunity.HemaSphere · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmodium parasites invade and multiply inside red blood cells (RBC). Through a cycle of maturation, asexual replication, rupture and release of multiple infective merozoites, parasitised RBC (pRBC) can reach very high numbers in vivo, a process that correlates with disease severity in humans and experimental animals. Thus, controlling pRBC numbers can prevent or ameliorate malaria. In endemic regions, circulating parasite-specific antibodies associate with immunity to high parasitemia. Although in vitro assays reveal that protective antibodies could control pRBC via multiple mechanisms, in vivo assessment of antibody function remains challenging. Here, we employed two mouse models of antibody-mediated immunity to malaria, P. yoelii 17XNL and P. chabaudi chabaudi AS infection, to study infection-induced, parasite-specific antibody function in vivo. By tracking a single generation of pRBC, we tested the hypothesis that parasite-specific antibodies accelerate pRBC clearance. Though strongly protective against homologous re-challenge, parasite-specific IgG did not alter the rate of pRBC clearance, even in the presence of ongoing, systemic inflammation. Instead, antibodies prevented parasites progressing from one generation of RBC to the next. In vivo depletion studies using clodronate liposomes or cobra venom factor, suggested that optimal antibody function required splenic macrophages and dendritic cells, but not complement C3/C5-mediated killing. Finally, parasite-specific IgG bound poorly to the surface of pRBC, yet strongly to structures likely exposed by the rupture of mature schizonts. Thus, in our models of humoral immunity to malaria, infection-induced antibodies did not accelerate pRBC clearance, and instead co-operated with splenic phagocytes to block subsequent generations of pRBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.